Anti-Emetics & Emetics Pharmacology

Vomiting is a reflex action that involves the forceful expulsion of the stomach's contents. This process primarily occurs through the oral cavity, where the contents are ejected from the mouth. While the esophagus, pharynx, and even nasal cavity may be involved in the mechanics of vomiting, the final act of expulsion is distinctly through the oral cavity, making it the most accurate definition of the process.

The bilateral vomiting center is situated in the dorsal portion of the lateral reticular formation within the medulla. This area is crucial for coordinating the reflexive actions of vomiting, integrating sensory signals from the gastrointestinal tract and other parts of the body. The medulla's role in autonomic functions, including those related to nausea and vomiting, highlights its importance in maintaining homeostasis and responding to potential toxins or irritants.

The Chemoreceptor Trigger Zone (CTZ) is a critical area in the brain that detects toxins and triggers vomiting. It is primarily influenced by several neurotransmitters. Dopamine D2 receptors are involved in the emetic response, while 5-HT3 receptors are activated by serotonin, also contributing to nausea and vomiting. Opioid receptors can modulate these responses. Together, these receptors play a significant role in the CTZ's ability to respond to various stimuli, making them essential for understanding the mechanisms of nausea and vomiting.

Ondansetron is effective in preventing nausea and vomiting by specifically targeting 5-HT3 receptors located in the chemoreceptor trigger zone (CTZ) and the afferent vagal nerve terminals in the upper gastrointestinal tract. By blocking these receptors, ondansetron inhibits the signals that trigger the vomiting reflex, thus providing relief from nausea. The CTZ is responsible for detecting toxins in the blood, while the vagal nerve terminals respond to gastrointestinal disturbances, making these sites crucial for emesis control.

Ondansetron is a 5-HT3 receptor antagonist, which means it primarily targets serotonin receptors to prevent nausea and vomiting. However, in the case of motion sickness, the vestibular nuclei, which are involved in balance and spatial orientation, do not have 5-HT3 receptors. Instead, they primarily possess muscarinic and H1 histamine receptors. This means that Ondansetron's mechanism of action is ineffective for motion sickness-related nausea, as it does not interact with the relevant receptors in the vestibular system that mediate this type of nausea and vomiting.

Metoclopramide primarily acts as a dopamine D2 receptor antagonist, but at higher doses, it also blocks 5-HT3 receptors. This dual action enhances its antiemetic effects, particularly in preventing nausea and vomiting. The antagonism of 5-HT3 receptors is crucial because these receptors are involved in the vomiting reflex, especially in response to chemotherapy and other triggers. By targeting both D2 and 5-HT3 receptors, metoclopramide provides a more comprehensive approach to managing nausea and vomiting.

Phenothiazines and butyrophenones can exacerbate symptoms of Parkinson's disease due to their dopamine antagonist properties, which may lead to increased extrapyramidal side effects. These medications can worsen motor function and cause additional complications in patients with Parkinson's, making their use contraindicated in this population. In contrast, they may be appropriate for other types of emesis, such as chemotherapy-induced or radiation-induced nausea, where the benefits may outweigh the risks.

Droperidol, an antipsychotic and antiemetic medication, is known to cause QT prolongation, which can lead to torsade de pointes, a potentially life-threatening form of ventricular tachycardia. This cardiac adverse effect is particularly concerning in patients with existing cardiovascular conditions, as it increases the risk of arrhythmias. Due to this association, healthcare providers exercise caution when prescribing droperidol to individuals with a history of heart disease or arrhythmias, limiting its use in these populations to prevent serious complications.

Scopolamine is favored over Atropine for its effectiveness as an antiemetic due to its ability to act more selectively on the central nervous system (CNS), leading to better control of nausea and vomiting. Additionally, Scopolamine has a longer duration of action, which makes it suitable for preventing motion sickness over extended periods. This selective CNS action reduces peripheral side effects, making it a more tolerable option for patients compared to Atropine, which may have more pronounced adverse effects on peripheral systems.

Transdermal delivery of Scopolamine via a skin patch provides sustained release of the medication, allowing it to be absorbed gradually through the skin into the bloodstream. This method is designed for prolonged therapeutic effects, particularly in preventing nausea and vomiting associated with motion sickness or postoperative conditions. The patch typically delivers Scopolamine continuously for up to 72 hours, offering a convenient and effective means of managing symptoms without the need for frequent dosing.

Dronabinol, a synthetic form of THC, primarily exerts its antiemetic effects by activating CB1 cannabinoid receptors located in the brain, particularly in the vomiting center. This stimulation modulates neurotransmitter release and decreases the excitability of neurons responsible for vomiting, thereby reducing nausea and vomiting associated with chemotherapy and other conditions. The interaction with CB1 receptors is crucial for its therapeutic action, distinguishing it from other receptor types involved in emesis.

Aprepitant is specifically designed to target the delayed phase of chemotherapy-induced emesis, which typically occurs more than 24 hours after chemotherapy administration. This phase is characterized by nausea and vomiting that can persist for several days following treatment. Aprepitant works by blocking the neurokinin-1 (NK1) receptors in the brain, which are involved in the vomiting reflex. By inhibiting these receptors, aprepitant effectively reduces the severity and frequency of vomiting during this delayed phase, improving patient comfort and adherence to chemotherapy regimens.

Ipecac syrup induces vomiting primarily by stimulating the chemoreceptor trigger zone (CTZ) located in the medulla, which is responsible for the vomiting reflex. Additionally, it acts directly on the gastric mucosa, enhancing the sensation of nausea and promoting the emetic response. This dual action effectively triggers the vomiting mechanism, making ipecac an effective emetic agent in certain situations.

Cyclizine and Meclizine are first-generation antihistamines that are effective for treating nausea and vomiting, particularly in pregnancy. They work by blocking histamine receptors in the brain that trigger nausea. These medications have a favorable safety profile during pregnancy, making them a preferred choice for managing symptoms without posing significant risks to the developing fetus. Other antihistamines listed may not be as effective or safe for pregnant individuals, which reinforces the selection of Cyclizine and Meclizine for this specific condition.

Phenothiazines and Butyrophenones function as antiemetics primarily by blocking dopaminergic D2 receptors in the chemoreceptor trigger zone (CTZ) of the brain. This action reduces the stimulation of the vomiting center, thereby alleviating nausea and vomiting. Additionally, these medications inhibit peripheral transmission to the vomiting center and block alpha-1 adrenoceptors, further enhancing their antiemetic effects. By targeting these pathways, they effectively prevent the physiological responses associated with nausea and vomiting, making them valuable in managing these symptoms.